NCT02042885终止1 期
A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 79
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose / Recommended Phase 2 dose; Tolerability
研究概览
简要总结
The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years of age
- •Patients with prostate cancer that is recurrent or did not respond to previous hormone therapy and/or who have exhausted standard treatment options.
- •For the dose escalation parts only:
- •Patients who have exhausted standard treatment options with recurrent or refractory cancer (ovarian cancer, cervical squamous cell carcinoma, breast cancer, salivary gland cancer, endometrial cancer)
- •Histologically or cytologically documented diagnosis of cancer
- •Measurable disease according to RECIST Version 1.1 or for prostate cancer also evaluable disease according to Prostate Cancer Working Group 2 (PCWG2) eligibility criteria or for ovarian cancer also evaluable disease (non-measurable) according to Gynaecologic Cancer Intergroup (GCIG) criteria
- •Absolute neutrophil count ≥1.5 (1500/mm3) and platelets ≥100 × 109/L (without platelet transfusion within the last 4 weeks before first study drug administration), and haemoglobin ≥9 g/dL at Screening
- •Alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal (ULN), Total bilirubin ≤1.5 × ULN (exception: patients with liver metastasis are allowed to have aspartate aminotransferase ≤5 × ULN and alanine aminotransferase ≤5 × ULN) at screening
- •Albumin ≥26 g/L at Screening
排除标准
- •Concurrent prior treatment-related toxicity of Grade 2 or higher. Exception: any toxicity that is in the view of the investigator not a clinically significant safety risk for Investigational medicinal product (IMP) administration.
- •Previous treatment with cytotoxic chemotherapy or other anticancer therapy within 4 weeks before the first dosing with study drug (at least 6 weeks for mitoxantrone, nitrosurea, and bicalutamide).
- •Treatment with systemic glucocorticosteroids of more than a 2 mg dexamethasone equivalent per day or in cases of treatment with ≤2 mg dexamethasone equivalent per day:
- •Dosing was changed within 6 weeks before Screening or
- •The patient's cancer is responding to glucocorticosteroid intake
- •Radiation therapy within 4 weeks prior to the first dosing with IMP.
- •Treatment with a systemic IMP in a clinical trial within 28 days before the Screening Visit.
- •Current or past history of clinically significant gastrointestinal disease or major gastrointestinal surgery, malabsorption syndrome, or other conditions that could interfere with enteral absorption.
- •Concurrent clinically significant unrelated systemic illness (e.g., serious infection) or significant pulmonary, hepatic, or other organ dysfunction that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results.
研究组 & 干预措施
1: Regimen A Escalation
Experimental
1: OPB-111001, orally, once weekly
干预措施: OPB-111001 (Drug)
2: Regimen A Extension
Experimental
2: OPB-111001, orally, once weekly
干预措施: OPB-111001 (Drug)
3: Regimen B Escalation
Experimental
3: OPB-111001, orally, 2 - 3 times per week
干预措施: OPB-111001 (Drug)
4: Regimen B Extension
Experimental
4: OPB-111001, orally, 2 - 3 times per week
干预措施: OPB-111001 (Drug)
结局指标
主要结局
Maximum tolerated dose / Recommended Phase 2 dose; Tolerability
时间窗: after 2 or 6 weeks depending on study part; continously
次要结局
- Pharmacokinetic parameters for OPB-111001 and its metabolites(repeatedly until end of study (average of 3 months assumed))
- Assessment of antitumor activity as defined by Response Evaluation Criteria in Solid Tumours (RECIST)(repeatedly every 8th week until end of study (average of 3 months assumed))
- Prostate-specific antigen (PSA) response in patients with prostate cancer(repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed))
- Cancer antigen 125 (CA 125) response in patients with ovarian cancer(repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed))
- Time to treatment failure(At end of study (after average of 3 months assumed))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced CancerSolid TumorsNCT01711034Otsuka Pharmaceutical Development & Commercialization, Inc.145
已完成
1 期
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid LeukaemiaAcute Myeloid LeukemiaNCT03197714Hospital Universitario 12 de Octubre9
已完成
1 期
STAT3 Inhibitor for Solid TumorsAdvanced CancerSolid TumorNCT00955812M.D. Anderson Cancer Center24
Unknown
2 期
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077Refractory TumorNPCNCT03158324National University Hospital, Singapore52
尚未招募
1 期
Safety and Efficacy of DCB-BO1301 in Advanced MelanomaAdvanced MelanomaNCT02994498Chung Mei Biopharma Co., Ltd33